Study the Efficacy of Sorafenib, Vemurafenib and Dabrafenib on BRAF Wild and Mutated Genes Using Computational Approach

Authors: Alla MH, Enas AS, Asia M, Salah MB, Anton H and Abdul MG*

DOI: 10.23880/apct-16000127

Volume 3, Issue 2

Abstract

The BRAF gene provides instructions for making a protein that helps transmit chemical signals from outside the cell to the cell's nucleus. Activation of the BRAF/MAPK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway has been shown to increase tumor cell proliferation, survival, invasion, and tumor angiogenesis. The BRAF gene is an oncogene and when it is mutated it turns the normal cells to become cancerous. Molecular docking showed that sorafenib, vemurafenib and dabrafenib are inhibitors that have the potential to inhibit the activity of many tumours related to BRAF mutations. In conclusion, BRAF inhibitors, such as Sorafenib, vemurafenib and dabrafenib, are specifically active against BRAF-mutant carcinoma.

Keywords: BRAF; Tumour; Sorafenib; Vemurafenib; Dabrafenib

View PDF